Weaver Kirke 4

What Happened

• Weaver Kirke, General Counsel and Corporate Secretary of Organon & Co. (OGN), received a grant of 183,639 restricted stock units (RSUs) on March 31, 2026. The RSUs were awarded at $0.00 (grant of derivative securities) and will convert to common shares if/when they vest.
• On the same date, previously granted RSUs vested/converted into shares: 6,201 and 12,312 shares were recorded as exercised/converted (derivative-to-share events). To satisfy tax withholding obligations, a total of 5,275 shares were surrendered (1,767 + 3,508) at the plan-required price of $5.70 per share, yielding tax withholdings of $10,072 and $19,996 respectively (total $30,068).

Key Details

• Transaction date: March 31, 2026. Withholding price: $5.70 (Organon closing share price on March 30, 2026, per filing).
• Grant: 183,639 RSUs (each RSU represents the contingent right to one share). Vesting schedule: three equal installments on Mar 31 of 2027, 2028 and 2029 (see footnote F2).
• Vesting/conversion: Prior RSU grants vested on Mar 31, 2026 (6,201 and 12,312 shares converted to shares per F4–F5).
• Tax withholding: 5,275 shares surrendered to cover taxes, total withholding value $30,068 (reported as dispositions under code F).
• Shares owned after the transactions: not specified in the Form 4 filing.
• Filing timeliness: No late filing is indicated in the provided filing information.

Context

• Transaction codes: A = award/grant (RSUs); M = exercise/conversion of derivative (RSU conversion to shares); F = payment of exercise price or tax liability (share withholding to cover taxes).
• The RSU grant is not an open-market purchase (it's a compensation award). The converted RSUs and the withholding are routine administrative actions to reflect vesting and tax obligations, not an open-market buy or sell signal.